ADCs (Everic© lyo & amber)

Unlock the potential of ADC packaging that safeguards every molecule. Antibody-drug conjugates (ADCs) are a fast-growing class of biopharmaceuticals, projected to reach €53 billion by 2030 with over 3,000 active patents by 2025 (GlobalData, May 2025). Their complex structure - monoclonal antibody, linker, and cytotoxic payload - enables targeted cancer therapy but demands packaging that ensures stability, safety, and efficacy. EVERIC® amber vials provide ideal primary packaging for light-sensitive products like ADCs and other biologics. Paired with EVERIC® lyo vials, they create optimal conditions for lyophilized products, preventing fogging and improving residual emptying. Suitable for both bulk and ready-to-use applications, EVERIC® lyo & amber delivers reliability throughout the drug lifecycle.